Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
D004999:Amifostine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D003680:Deglutition Disorders / Q000209:etiology* / Q000517:prevention & control; D004408:Dysgeusia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000532:radiotherapy*; D006801:Humans; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D013280:Stomatitis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D014987:Xerostomia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control
D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D004999:Amifostine